Juan Carlos Amat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juan Carlos Amat has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Gutierrez
Hematology Department Hospital Universitario Son Espases, IdISBa Palma De Mallorca Spain
2 shared publications - Jordi Martinez-Serra
Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain
2 shared publications - Julio Iglesias
Department of Immunology, University Hospital Son Espases, Palma de Mallorca, Spain
2 shared publications - María Antonia Durán
Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain
2 shared publications - Antonia Sampol
Clinical Practice and Biology of the Hematological Malignancies Research Group, IdISBa, Son Espases University Hospital, 07120 Palma de Mallorca, Spain
1 shared publication - Bernardo López Andrade
Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Hospital Universitario Son Espases Palma de Mallorca Balearic Islands Spain
1 shared publication
Latest Publications
- Open Access
- 1 December 2015
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 5 (1) , 1-5
Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases
- 1 December 2015
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 5 (1) , 1-5
Open AccessAcute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases
- Open Access
- 14 August 2014
- Published by Springer Nature in Biomarker Research
- Vol. 2 (1) , 14
Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis
Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a hematopoietic stem cell. CML is cytogenetically characterized by the presence of the Philadelphia chromosome (Ph’). Most patients with CML express e13a2 or e14a2 mRNAs that result from a rearrangement of the major breakpoint cluster regions (M-BCR) generating the 210-kDa (p210BCR-ABL) fusion proteins b2a2 or b3a2 respectively. The e1a3 CML-related atypical translocation has been reported with an indolent clinical course, low leukocyte count, long chronic phase even without treatment and good response to therapy. We report the case of a patient initially diagnosed as CML in chronic phase whose cells expressed the e1a3 variant. The patient readily responded to imatinib 400 mg with the achievement of a rapid complete cytogenetic response and the normalization of the blood count values, but after 5 months transformed into lymphoid blast crisis.
- 14 August 2014
- Published by Springer Nature in Biomarker Research
- Vol. 2 (1) , 14
Open AccessChronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis
Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a hematopoietic stem cell. CML is cytogenetically characterized by the presence of the Philadelphia chromosome (Ph’). Most patients with CML express e13a2 or e14a2 mRNAs that result from a rearrangement of the major breakpoint cluster regions (M-BCR) generating the 210-kDa (p210BCR-ABL) fusion proteins b2a2 or b3a2 respectively. The e1a3 CML-related atypical translocation has been reported with an indolent clinical course, low leukocyte count, long chronic phase even without treatment and good response to therapy. We report the case of a patient initially diagnosed as CML in chronic phase whose cells expressed the e1a3 variant. The patient readily responded to imatinib 400 mg with the achievement of a rapid complete cytogenetic response and the normalization of the blood count values, but after 5 months transformed into lymphoid blast crisis.